Visible Genomics provides genetic testing for age-related macular degeneration (AMD) risk assessment, enabling the identification of individuals predisposed to this condition. This clinically validated service facilitates proactive monitoring and early intervention to reduce the likelihood of vision loss associated with AMD.
Funding
$190K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Age-related macular degeneration (AMD) affects millions, and a significant portion of its cause is genetic, making early risk assessment crucial. Current methods for assessing AMD risk may not fully incorporate genetic factors, potentially delaying proactive intervention.
Solution
Visible Genomics offers AMD genetic testing services to provide a comprehensive risk assessment based on an individual's DNA and health factors. Their AMDiGuard tests analyze specific genetic markers associated with AMD to determine a patient's risk level and potential for disease progression. This information empowers both patients and physicians to make informed decisions about lifestyle changes, monitoring frequency, and preventative treatments. By integrating genetic insights, Visible Genomics enables personalized care plans aimed at slowing or preventing vision loss associated with AMD.
Target Audience
The primary target audience includes individuals with a family history of AMD, those exhibiting early signs of the disease, and eye care professionals (ophthalmologists and optometrists) seeking advanced diagnostic tools for personalized patient care.
Features
- AMDiGuard DNA Risk Test: Assesses the overall risk of developing age-related macular degeneration using a simple swab and health data.
- AMDiGuard DNA Progression Test: Evaluates the risk of advanced AMD in patients already diagnosed with early to intermediate stages of the disease.
- Comprehensive genetic analysis: Identifies relevant genetic markers associated with AMD susceptibility and progression.
- Personalized risk reports: Provides clear and understandable risk assessments tailored to individual patient profiles.
- Integration with clinical protocols: Facilitates the incorporation of genetic testing into existing AMD management strategies.